Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
AssigneeTakeda Pharmaceutical Company Limited
InventorsAntara Banerjee, Andrea Fanjul, Robert J. Hoey, Kacey Sachen, Nikolai Suslov
Life of this patent
Estimating the term…
Abstract
The present disclosure provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragment thereof. The CB1 binding proteins find utility in the treatment and diagnosis of CB1 mediated conditions, diseases and disorders.
Claims35
An isolated antibody or antigen-binding fragment thereof that binds human cannabinoid type 1 receptor (CB1) (SEQ ID NO:1), wherein the antibody or antigen-binding fragment comprises six complementarity determining regions (CDRs):
- CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3, wherein
- CDR-H1 has an amino acid sequence S-Y-T-F-T-R-Y-W;
- CDR-H2 has an amino acid sequence I-D-P-Y-D-S-E-T;
- CDR-H3 has an amino acid sequence A-R-S-Q-P-R-Y-Y-A-M-D-Y;
- CDR-L1 has an amino acid sequence Q-E-I-S-G-F;
- CDR-L2 has an amino acid sequence:
- A-A-S;
- and
- CDR-L3 has an amino acid sequence:
- L-Q-Y-S-S-Y-P-Y-T.
2-7. (canceled)
(canceled)
(canceled)
(canceled)
34-36. (canceled)
38-56. (canceled)
58-61. (canceled)
(canceled)
Dependencies are inferred from the claim text.